Lyell Immunopharma (LYEL) Invested Capital: 2019-2025
Historic Invested Capital for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to $329.1 million.
- Lyell Immunopharma's Invested Capital fell 37.98% to $329.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $329.1 million, marking a year-over-year decrease of 37.98%. This contributed to the annual value of $382.8 million for FY2024, which is 41.55% down from last year.
- According to the latest figures from Q3 2025, Lyell Immunopharma's Invested Capital is $329.1 million, which was up 10.10% from $298.9 million recorded in Q2 2025.
- In the past 5 years, Lyell Immunopharma's Invested Capital registered a high of $1.0 billion during Q2 2021, and its lowest value of -$334.0 million during Q1 2021.
- Over the past 3 years, Lyell Immunopharma's median Invested Capital value was $566.5 million (recorded in 2024), while the average stood at $538.3 million.
- In the last 5 years, Lyell Immunopharma's Invested Capital surged by 525.62% in 2021 and then slumped by 47.23% in 2025.
- Over the past 5 years, Lyell Immunopharma's Invested Capital (Quarterly) stood at $929.8 million in 2021, then dropped by 10.38% to $833.3 million in 2022, then fell by 21.40% to $655.0 million in 2023, then crashed by 41.55% to $382.8 million in 2024, then slumped by 37.98% to $329.1 million in 2025.
- Its Invested Capital was $329.1 million in Q3 2025, compared to $298.9 million in Q2 2025 and $336.5 million in Q1 2025.